ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP63-19 When the Authorization Tool is Utilized on the Availity Portal
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 26, 2019
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2321 - 2330 လၢ 3613 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP58-19 Pharmacy Benefit Exclusion for Zolgensma (onasemnogene abeparvovec-xioi) Injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP56-19 Pharmacy Benefit Update – New Drug-Related Step Therapy Criteria: Topical Corticosteroids
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP48-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Somatostatin Analogs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP47-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Hereditary transthyretin-mediated (hATTR) Amyloidosis Neuropathy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP57-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization Criteria: tafamidis
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP49-19 Pharmacy Benefit Exclusion for Proventil (albuterol sulfate) HFA and Proventil (albuterol sulfate) HFA Authorized Generic (AG)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP54-19 Pharmacy Benefit Update – New Drug-Related Utilization Management Program: Opioid Immediate Release (IR) New to Therapy (NTT) Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP52-19 Pharmacy Benefit Exclusion for Cimzia, Elzonris, Gamifant, Kalbitor, Khapzory, leucovorin calcium, Nuzyra and Panzyga
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP53-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Neurotrophic Keratitis
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019